Allecra Therapeutics to present data at 28th European Congress of Clinical Microbiology and Infectious Diseases

Lörrach, Germany and Saint-Louis, France, April 16, 2018 (GLOBE NEWSWIRE)—Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced six upcoming presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 21-24 in Madrid, Spain at the IFEMA-Feria de Madrid. The Company and its collaborators will deliver presentations containing information about the Company’s lead drug, AAI101, an extended-spectrum β‑lactamase inhibitor, in combination with cefepime. The combination of AAI101 with cefepime is in clinical development for treatment of complicated urinary tract infections, including acute pyelonephritis, by MDR Gram-negative bacteria.

“We are excited to share data from six posters at ECCMID this year. Each of these presentations adds to the growing body of evidence in favour of cefepime/AAI101 to treat certain kinds of Gram-negative bacterial resistance. Allecra’s cefepime/AAI101 development program targets resistance frequently encountered with Gram-negative hospital pathogens which often harbor extended-spectrum β‑lactamases (ESBLs),” said Nicholas Benedict Co-Founder and Chief Executive Officer of Allecra Therapeutics. “These presentations represent our ongoing commitment to make Allecra’s data accessible to practicing physicians.”

Details for the poster presentations at ECCMID 2018 are as follows:

Presentation title: Activity of the novel extended-spectrum β-lactamase inhibitor AAI101 in combination with cefepime against Enterobacteriaceae collected from US and European hospitals during 2014/2015.
Date and time: April 24, 2018 12:30-13:30 CET 
Location: Paper Poster Arena
Presentation number:  P2415
Lead author: Ian Morrissey
Session information: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

Session information: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data
Presentation title:  Activity of a novel extended-spectrum β-lactamase inhibitor, AAI101, combined with cefepime against β-lactamase-producing Enterobacteriaceae in a neutropenic murine pneumonia model.
Date and time: April 24, 2018 12:30-13:30 CET
Location: Paper Poster Arena
Presentation number:   P2418
Lead author: Peter Warn
Session information: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

Presentation title:  In vitro activities of AAI101, a novel extended-spectrum β-lactamase inhibitor, and tazobactam, in combination with cefepime, against extended-spectrum β-lactamase producing Klebsiella pneumoniae clinical isolates.
Date and time: April 24, 2018 12:30-13:30 CET
Location: Paper Poster Arena
Presentation number:  P2423
Lead author: Ian Morrissey
Session information: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

Presentation title:  Activity of a novel extended-spectrum β-lactamase inhibitor, AAI101, combined with cefepime against β-lactamase-producing Enterobacteriaceae in a murine septicemia model.
Date and time: April 24, 2018 12:30-13:30 CET
Location: Paper Poster Arena
Presentation number:   P2424
Lead author: Cédric Jacqueline
Session information: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

Presentation title:  Cefepime-AAI101 and cefepime MIC quality-control ranges using a CLSI M23-A4 multi-laboratory study design.
Date and time: April 24, 2018 12:30-13:30 CET
Location: Paper Poster Arena
Presentation number:  P2492
Lead author: Michael Huband
Session information: Various aspects of antimicrobial susceptibility testing

Presentation title:  Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101.
Date and time: April 21, 2018 15:30-16:30 CET
Location: Paper Poster Arena
Presentation number:  P0157
Lead author: Michael Huband

Session information: Antimicrobial susceptibility testing by disk diffusion

These abstracts can be accessed through the ECCMID Website. Following the meeting, the posters will be available on the company website.

Dated: 17/04/2018

""